Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 5/20 | 0.57 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.57 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.43 |
| ▸ | PDE9A | O76083 | 1/20 | 0.43 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.43 |
| ▸ | SPR | P35270 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30775343 | 0.90 | GRIN1 (0.50) | GRIN1GRIN2BCHRNB2CHRNA4AOC3 | |
| SCHEMBL30775253 | 0.87 | AOC3 (0.50) | GRIN1GRIN2BCHRNB2CHRNA4AOC3 | |
| SCHEMBL30775277 | 0.83 | GRIN1 (0.53) | GRIN1GRIN2BPDE9AOPRM1OPRK1 | |
| SCHEMBL27145844 | 0.77 | SPR (0.51) | GRIN1GRIN2BCHRNB2CHRNA4SPR | |
| SCHEMBL6123545 | 0.76 | HRH3 (0.51) | GRIN1GRIN2BCHRNB2CHRNA4SPR | |
| SCHEMBL13838838 | 0.76 | SPR (0.53) | GRIN1GRIN2BCHRNB2CHRNA4SPR | |
| SCHEMBL30775207 | 0.74 | CHRM2 (0.47) | GRIN1GRIN2BOPRK1EPHX2 | |
| SCHEMBL12819481 | 0.73 | CHRNB2 (0.54) | GRIN1GRIN2BCHRNB2CHRNA4 | |
| SCHEMBL20069120 | 0.73 | CHRNB2 (0.54) | GRIN1GRIN2BCHRNB2CHRNA4SPR | |
| SCHEMBL18307626 | 0.73 | NAMPT (0.55) | GRIN1GRIN2BCHRNB2CHRNA4SPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | claimed |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | DONG-A ST CO., LTD. (KR) | 2025-03-04 | — | — | US | disclosed |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | EIF2AK4, GCN1, GCGR | GRIN1 146/4885GRIN2B 300/4885CHRNB2 3816/4885 |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EIF2AK4, GCN1, GCGR | GRIN1 146/4885GRIN2B 300/4885CHRNB2 3816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.